-
Developed by our Chief Scientist David Tuveson, M.D., Ph.D., and his collaborator Hans Clevers, M.D., Ph.D., president of the Royal Netherlands Academy of Arts and Sciences, organoids are microscopic βcopiesβ […]
Oct 19,2021
-
CancerSEEK, developed by Lustgarten-funded researcher Dr. Bert Vogelstein and his team at Johns Hopkins Kimmel Cancer Center, can detect the early presence of multiple cancers, including pancreatic cancer, and also […]
Oct 19,2021
-
Oct 18,2021
-
New research from a team of investigators at theΒ Mayo Clinic Comprehensive Cancer CenterΒ has found that the use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds prognostic benefit for […]
Sep 12,2022
-
Pancreatic cancer is considered one of the most difficult cancers to treat, with a five-year survival rate of only 11 percent. Researchers at Duke University are trying to change that. […]
Jan 04,2023
-
An extremely common response to cellular stress may be the key to pancreatic cancer in people with obesity, pointing to a new direction for therapy of this difficult-to-treat cancer.
Sep 21,2022
-
Scientists from Northeastern University are partnering with UC Davis and drug developer TargaGenix on the final research stages of a new therapeutic model they say could transform treatment for pancreatic […]
Mar 01,2023
-
The Lustgarten Foundationβs Research Investigator Program funds talented scientists with historical accomplishments in cancer research to focus on pancreatic cancer. Scientists receive three-year grants for projects investigating the science underlying […]
Oct 08,2021